Page 8 - Ancer Prostate News Today

The addition of PSMA-PET/CT to MRI-target biopsy changed treatment plans for most patients with clinically significant tumors, but some experts note that the cost may outweigh the benefit.

When a 68-year-old man in Norway died of infection after a transrectal biopsy, his daughter urged change. Four years later, that campaign looks to be a success ― but the US has moved slowly to adapt.

A large study from Germany found that digital rectal examination had low detection rates compared with prostate-specific antigen testing in men in their mid-to-late 40s.

Men with newly diagnosed non-metastatic prostate cancer who were randomly assigned to surgery, radiation, or active monitoring had similar overall and prostate cancer-specific survival rates after 15 years.

Incorporating peer coaching from a genetics expert into the community oncology setting helped increase uptake of germline genetic testing among eligible patients.

First-line systemic therapy in patients with metastatic castration-sensitive prostate cancer should be based on individual disease and patient characteristics, results of a meta-analysis suggest.

In a subset of patients with high-risk prostate cancer, the combination of abiraterone acetate plus prednisone (AAP) and apalutamide may improve outcomes when added to salvage radiation therapy.

Members of Congress are pushing to test whether costs of certain US drugs could be lowered by using the Bayh-Dole "march-in" provision on patent rights regarding discoveries supported by federal money.

The widespread use of aggressive care at the end of life for nursing home residents with metastatic cancer suggests the increased emphasis on less intensive care is not getting through, suggests US research.

Big data and artificial intelligence could lead the way in future cancer research and clinical care.